This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Driving (surgical craniotomy, benign supratentorial tumour)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Benign supratentorial tumour

  • WHO grade I meningiomas treated by craniotomy

Group 1 entitlement:

  • Must not drive and must notify the DVLA
  • Driving may resume after 6 months provided there is no debarring residual impairment likely to affect safe driving, and no history of seizures
  • If the tumour has been associated with seizures, driving must cease for 12 months following surgery and 12 months from the date of the most recent seizure
  • WHO grade II meningiomas treated with craniotomy and/or radiosurgery and/or radiotherapy
    • Group 1 entitlement:
      • Must not drive and must notify the DVLA.
      • Driving may resume 1 year after completion of treatment
      • epilepsy regulations apply if relevant history of seizure(s)

  • Asymptomatic incidental meningiomas not needing treatment
    • May drive and need not notify the DVLA

Up-to-date guidance may be obtained from the publication "At a Glance Guide to the Current Medical Standards of Fitness to Drive" and the website www.dvla.gov.uk.

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.